Latest tauopathy Stories
TauRx Publishes Positive Results of Phase II Clinical Trial in the Journal of Alzheimer's Disease ABERDEEN, Scotland and SINGAPORE, Jan.
TauRx Chairman Prof. Claude Wischik brings a clinical trial opportunity directly to caregivers and patients at breakfast event PHILADELPHIA and LONDON, Oct.
New Study Shows Link between Plaques and Tangles/Could Open Door to Therapeutic Target Boston (PRWEB) October 13, 2014 In what is being hailed by scientists
Detection, at the Icahn School of Medicine at Mount Sinai, while the patient is still alive improves accuracy of diagnosis and enables estimation of prevalence and risk. New
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society.
Study indicates potential for TauC3 to be disease-modifying. Englewood Cliffs, New Jersey (PRWEB) January 16, 2014 Intellect Neurosciences, Inc.
Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer's disease ABERDEEN, Scotland, Jan.
Researchers have created a new class of imaging agents that could allow them to view the biological processes that occur in the brain during the development and progression of Alzheimer’s disease.
- A political dynamiter.